CryoPort, Inc. (NASDAQ:CYRX) Receives $15.31 Average Price Target from Analysts

CryoPort, Inc. (NASDAQ:CYRX) has been assigned an average rating of “Moderate Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $15.1111.

Several research firms recently commented on CYRX. Guggenheim lifted their target price on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. KeyCorp raised their price target on shares of CryoPort from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Craig Hallum raised their price target on shares of CryoPort from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a report on Monday, May 11th.

CryoPort Price Performance

NASDAQ:CYRX opened at $14.62 on Friday. The firm’s 50 day simple moving average is $12.42 and its 200 day simple moving average is $10.33. CryoPort has a one year low of $6.16 and a one year high of $16.73. The company has a market cap of $736.85 million, a PE ratio of 10.83 and a beta of 1.90.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The business had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. Equities research analysts expect that CryoPort will post -0.85 EPS for the current year.

Insider Activity

In other CryoPort news, CFO Robert Stefanovich sold 169,427 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the completion of the transaction, the chief financial officer owned 109,850 shares in the company, valued at approximately $1,787,259.50. This trade represents a 60.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Edward J. Zecchini sold 33,600 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $14.47, for a total transaction of $486,192.00. Following the transaction, the insider owned 109,719 shares of the company’s stock, valued at approximately $1,587,633.93. The trade was a 23.44% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 248,880 shares of company stock worth $3,793,387. 10.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CYRX. AQR Capital Management LLC raised its holdings in CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after purchasing an additional 194,482 shares during the last quarter. Creative Planning bought a new stake in shares of CryoPort in the 2nd quarter valued at $96,000. Rhumbline Advisers increased its stake in shares of CryoPort by 17.6% in the 2nd quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock valued at $687,000 after acquiring an additional 13,778 shares in the last quarter. American Century Companies Inc. increased its stake in shares of CryoPort by 24.4% in the 2nd quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock valued at $663,000 after acquiring an additional 17,459 shares in the last quarter. Finally, Prudential Financial Inc. bought a new stake in shares of CryoPort in the 2nd quarter valued at $254,000. Institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.